Cepheid Inc - Company Profile
Powered by
All the data and insights you need on Cepheid Inc in one report.
- Save hours of research time and resources with
our up-to-date Cepheid Inc Strategy Report
- Understand Cepheid Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Cepheid Inc (Cepheid), a subsidiary of Danaher Corp, is a molecular diagnostic company that develops, manufactures, and markets molecular systems and conducts tests for clinical and non-clinical markets. The company offers in vitro diagnostic tests for health care-associated infections, critical infectious diseases, sexual health, virology, oncology and genetics; molecular diagnostic systems; and reagents and parts. Cepheid distributes its products directly and through a network of distributors present across the Americas, Asia, Europe, Africa and the Middle East. The company also offers various services such as maintenance, software updates, repair, and support among others. Cepheid is headquartered in Sunnyvale, California, the US.
Cepheid Inc premium industry data and analytics
Products and Services
Products | Services | Brands |
---|---|---|
- | - | - |
Healthcare Associated Infections: | Maintenance | Cepheid |
Xpert MRSA NxG | Support | SmartCycler |
XYZ | XYZ | XYZ |
XYZ | XYZ | XYZ |
XYZ | XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2024 | Regulatory Approval | In March, the company received clearance from the U.S. Food and Drug Administration for Xpert Xpress GBS, a dual-target molecular diagnostic test for the qualitative intrapartum detection of Group B Streptococcus (GBS). |
2024 | Regulatory Approval | In January, the company received FDA clearance with Clinical Laboratory Improvement Amendments (CLIA) waiver for Xpert Xpress MVP. |
2023 | Contracts/Agreements | In August, the company entered into an agreement with U.S. Army Health Contracting for SARS-CoV-2 and Streptococcus pyogenes testing. |
Competitor Comparison
Key Parameters | Cepheid Inc | Hologic Inc | Meridian Bioscience Inc | GenMark Diagnostics Inc | Binx Health Inc |
---|---|---|---|---|---|
Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
City | Sunnyvale | Marlborough | Cincinnati | Carlsbad | Cambridge |
State/Province | California | Massachusetts | Ohio | California | Massachusetts |
No. of Employees | - | 6,990 | - | - | - |
Entity Type | Private | Public | Private | Private | Private |
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Charles Mwangi | Senior Vice President; Chief Financial Officer | Senior Management | 2023 | - |
Jonathan Siegrist | Head - Assay R&D; Chief Technology Officer | Senior Management | - | - |
David H. Persing | Chief Medical Officer; Executive Vice President; Chief Scientific Officer | Senior Management | - | - |
Ashish Nanda | Chief Information & Transformation Officer | Senior Management | - | - |
Vitor Rocha | President | Senior Management | 2023 | - |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer